Biotechnology

Moleculin Biotech

Moleculin Biotech released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.5422 (forecast USD -1.6633)

Moleculin Biotech released FY2025 annual earnings on March 18 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -28.4187 (forecast USD -36.35)

Moleculin Biotech released FY2025 Q4 earnings on March 18 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 6.8995 (forecast USD -6.1133)

H.C. Wainwright reiterates buy rating on Moleculin Biotech

Moleculin Biotech released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.0214 (forecast USD -6.5833)

Moleculin Biotech released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 0 and EPS of USD -61.5203

Moleculin Biotech Enters into Research Agreement with UNC Chapel Hill for Annamycin Pancreatic Cancer Therapy

Moleculin Biotech Obtains Annamycin Patent in Australia

Moleculin Biotech Launches Annamycin Clinical Trial for Late-Stage Pancreatic Cancer

Moleculin Biotech Receives Patent Allowance Notice for Liposomal Annamycin

Moleculin Biotech released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -47.0917

Moleculin Biotech released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0911 (forecast USD -0.4033)

Moleculin Biotech Signs $6.5 Million Market Offering Agreement

Moleculin Biotech Expands AML Clinical Trial Sites

Moleculin Biotech Receives Nasdaq Delisting Warning

Moleculin Biotech CEO Buys Company Stock

Moleculin Biotech Files for Public Offering with Warrants

HC Wainwright Reiterates Buy Rating on Moleculin Biotech

Moleculin Biotech's Cancer Drug Annamycin Receives Positive FDA Feedback and Approval

Moleculin Biotech Annamycin Trial Fails to Reach Complete Remission, Stock Dips

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MBRX

LABU

SBIO

Preliminary data from the MIRACLE Trial reveals an impressive 40% overall complete remission rate in a challenging group of AML patients. This trial, which includes a diverse patient population, is showing promising results.

Unusual Whales

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Earnings Watch

Moleculin Biotech | 8-K: FY2026 Q1 Revenue: USD 0

Moleculin Biotech | 10-Q: FY2026 Q1 Revenue: USD 0

Analyst Jason McCarthy of Maxim Group has reiterated a Buy rating on Moleculin Biotech, maintaining a price target of $10. The decision is based on positive developments in the MIRACLE trial for annamycin in treating relapsed/refractory AML, showing higher remission rates compared to historical data. McCarthy believes these results reduce development risks and could serve as a significant value catalyst for MBRX, supporting future growth and justifying the price target.

Tip Ranks

Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target

CSCO

In the past hour, the overall market in the US stock market has shown a clear divergence, with technology and biotechnology sectors performing particularly well. Cisco's strong rise led the rebound in technology stocks, attracting a significant inflow of funds and significantly increasing short-term enthusiasm. Meanwhile, the decline of Kingsoft Cloud indicates a cautious sentiment towards certain individual stocks, with fund preferences seemingly switching between high-risk and low-risk assets. The overall volatility has been large, and the activity of short-term traders has also increased. In the past hour, the stock with the largest movement was Cisco, which rose by 20.06%, becoming the market's focus. Its strong performance not only drove the rebound of the entire technology sector but also sparked investor enthusiasm, with short-term funds quickly pouring in, pushing the stock price to continue rising. Strong stocks: 1. Moleculin Biotech: up 10.75%, with increased market attention on its R&D progress and noticeable fund inflow. 2. Wolfspeed: up 9.58%, as optimism about its prospects driven by increasing demand for new energy pushed the stock price up. 3. Marvell Technology: up 5.25%, with active short-term funds in the context of a semiconductor industry recovery. 4. Nokia: up 4.96%, benefiting from the ongoing promotion of 5G construction, leading to positive market sentiment. Pressured stocks: 1. Kingsoft Cloud: down 9.04%, with increasing market concerns about its future profitability leading to fund outflows

Price Alert

Cisco

Kingsoft Cloud

Wolfspeed

Marvell Tech

Nokia Oyj

Alibaba

Sumitomo Mitsui Financial

U.S. stock market movement update: Cisco surged 20.06%, Moleculin Biotech rose 10.75%, Kingsoft Cloud fell 9.04%

In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology and biotechnology sectors performing particularly well. Cisco's strong rise led the rebound in technology stocks, attracting a significant inflow of funds and notably increasing short-term trading enthusiasm. Meanwhile, the education sector's Jianzhi Edu Tech faced considerable selling pressure, reflecting a polarization of market sentiment. The overall volatility was large, and the activity of short-term traders also increased. In the past hour, the stock with the largest movement was Cisco, which rose by 19.92%, becoming the market's focus. Funds seemed to react enthusiastically to its latest performance, driving the stock price up rapidly and boosting the sentiment of the entire technology sector. 

Strong stocks:
1. Moleculin Biotech: up 15.89%, recent market attention on its R&D progress has increased, with short-term funds actively participating.
2. Nokia: up 5.37%, stimulated by 5G-related news, the stock price has steadily risen, attracting the attention of many investors.
3. Marvell Technology: up 5.20%, with the recovery of semiconductor demand, the market holds an optimistic view of its prospects, and fund inflows are evident.
4. Applied Materials: up 3.30%, in the context of increased demand for semiconductor equipment, the stock price performed steadily, with short-term funds continuing to pay attention.
5. NVIDIA: up 3.27%, as the AI boom continues to ferment, its stock price has slightly risen, and market sentiment remains optimistic.

Stocks under pressure:
1. Jianzhi Edu Tech: down 8.83%, concerns about its future performance have intensified, leading to a significant outflow of funds

Jianzhi Edu Tech

Applied Materials

NVIDIA

U.S. stock market movement update: Cisco surged nearly 20%, Moleculin Biotech rose 15.89%, Jianzhi Edu Tech fell 8.83%

In the past hour, the overall market in the US stock market has shown a clear divergence, with technology and biotechnology sectors performing particularly well. The strong rise of Cisco and Moleculin Biotech has attracted a significant inflow of funds, indicating investors' preference for the technology and pharmaceutical sectors. Meanwhile, education and cloud computing-related stocks have faced considerable selling pressure, with the declines of Jianzhi Edu Tech and Kingsoft Cloud drawing market attention. Short-term enthusiasm has significantly increased among technology stocks, with greater volatility, and market sentiment seems to oscillate between optimism and caution. The stock with the largest movement in the past hour, Cisco, saw an increase of 20.27%, becoming the market focus. Its strong performance not only boosted the entire technology sector but also sparked investor interest in related tech stocks, with the inflow of short-term funds noticeably accelerating. 

Strong stocks:
1. Moleculin Biotech: up 19.63%, with increased market attention on its R&D progress and significant fund inflow.
2. Nokia: up 4.62%, with enhanced market expectations for its future growth due to the ongoing promotion of 5G technology.
3. Marvell Technology: up 4.18%, benefiting from the recovery of the semiconductor industry, with active short-term fund participation.
4. Faraday Future: up 3.02%, despite facing challenges, the market remains hopeful about its electric vehicle prospects.

Stocks under pressure:
1. Jianzhi Edu Tech: down 8.83%, with market concerns about the outlook for the education industry and noticeable fund outflows

Faraday Future Intelligent Electric

U.S. stock market movement update: Cisco surged 20.27%, Moleculin Biotech rose 19.63%, Jianzhi Edu Tech fell 8.83%

Moleculin Biotech (MBRX) is nearing the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial for Annamycin plus cytarabine in treating relapsed or refractory acute myeloid leukemia, with results expected before June 30, 2026. Initial data shows a composite complete remission rate above 40%, significantly higher than historical rates with cytarabine alone. The company is progressing towards potential regulatory approval, despite current financial challenges. Analysts rate MBRX stock as a Buy with a $22.00 price target, while AI analysis suggests a Neutral outlook due to financial performance concerns.

Moleculin Nears First Unblinding in Pivotal MIRACLE Trial

Moleculin Biotech(MBRX.US)